Unlock instant, AI-driven research and patent intelligence for your innovation.

Neramexane for the treatment of nystagmus

A technology for nystagmus and neramexane, which is applied in amine active ingredients, nervous system diseases, sensory diseases, etc., can solve problems such as clinical research of patients without nystagmus

Inactive Publication Date: 2010-03-24
MERZ PHARMA GMBH & CO KGAA
View PDF10 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] According to published reports, there are no clinical studies of neramexane in patients diagnosed with nystagmus

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Neramexane for the treatment of nystagmus
  • Neramexane for the treatment of nystagmus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0185] Example 1: Double-blind placebo-controlled experiment of neramexane for the treatment of nystagmus

[0186] The goal of this pilot program is to conduct a clinical trial to assess the efficacy of neramexane as a treatment for nystagmus. Nystagmus patients treated with neramexane would be expected to demonstrate functional improvements in both primary (e.g., visual acuity) and secondary (e.g., nystagmus intensity and enlarged nystagmus visual acuity) compared to placebo-treated patients [NAFX ], reading ability, etc.) outcomes.

[0187] Research design

[0188] The primary objective of the study was to investigate the safety and efficacy of daily doses up to 75 mg in the treatment of congenital spontaneous nystagmus compared with placebo. In addition, subgroups of up to 20 MS patients suffering from acquired nystagmus were included and analyzed in an exploratory manner. In both patient groups, the effect of treatment compared to placebo was assessed using a two-period...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the treatment of an individual diagnosed with nystagmus comprising administering to the individual an effective amount of a 1-aminoalkylcyclohexane derivative, for example neramexane or a pharmaceutically acceptable salt thereof, such as neramexane mesylate.

Description

【Technical field】 [0001] The present invention relates to the treatment of an individual diagnosed with nystagmus comprising administering to the individual an effective amount of a 1-aminoalkylcyclohexane derivative, such as neramexane or a pharmaceutically acceptable salt thereof, such as neramexane mesylate pregnancy. 【Background technique】 [0002] The present invention relates to methods of treating patients suffering from nystagmus. Nystagmus is defined as repetitive and involuntary eye movement (ie, shaking). These vibrations can be horizontal, vertical or twisted, or any combination of the three. Nystagmus is also sometimes called eye flutter or vibratory hallucinations. [0003] More than forty subtypes of nystagmus have been classified to date. Nystagmus can have congenital or acquired forms and can be further classified based on direction and / or speed of movement or underlying disease. Juvenile or congenital nystagmus can be spontaneous or associated with eye...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/13A61P27/10A61P27/02
CPCA61K31/13A61P25/00A61P27/02A61P27/10
Inventor A·汉施曼A·施特夫勒M·阿尔特豪斯
Owner MERZ PHARMA GMBH & CO KGAA